ArticleTherapeutics and clinical risk management2010
New advances in the treatment of gout: review of pegloticase.
Article in Therapeutics and clinical risk management, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 52 citations in OpenAlex.
- Reducing Immunogenicity of Pegloticase With Concomitant Use of Mycophenolate Mofetil in Patients With Refractory Gout: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2021Trial
- Tophaceous gout of the knee: successful treatment with transarterial microembolization.Skeletal radiology · 2026Article
- Article
- Article
- Uricase-Expressing Engineered Macrophages Alleviate Murine Hyperuricemia.Biomedicines · 2024Article
- Co-delivery of indomethacin and uricase as a new strategy for inflammatory diseases associated with high uric acid.Drug delivery and translational research · 2024Article
- Cloning, Heterologous Expression, and Characterization of a Neutral Uricase fromPolish journal of microbiology · 2023Article
- Review
- High MW polyethylene glycol prolongs circulation of pegloticase in mice with anti-PEG antibodies.Journal of controlled release : official journal of the Controlled Release Society · 2021Article
- Nanohybrids as Protein-Polymer Conjugate Multimodal Therapeutics.Frontiers in medical technology · 2021Review
- Evaluating the urate-lowering effects of different microbial fermented extracts in hyperuricemic models accompanied with a safety study.Journal of food and drug analysis · 2017Article
- A Trivalent Enzymatic System for Uricolytic Therapy of HPRT Deficiency and Lesch-Nyhan Disease.Pharmaceutical research · 2017Article
- Therapeutic approaches to chronic hyperuricemia and gout.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2014Review
- De novo engineering of a human cystathionine-γ-lyase for systemic (L)-Methionine depletion cancer therapy.ACS chemical biology · 2012Article
- Refractory gout attack.Case reports in medicine · 2012Article
- Profile of peginesatide and its potential for the treatment of anemia in adults with chronic kidney disease who are on dialysis.Journal of blood medicine · 2012Article
- The Hypouricemic Effect of Balanophora laxiflora Extracts and Derived Phytochemicals in Hyperuricemic Mice.Evidence-based complementary and alternative medicine : eCAM · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment-failure gout (TFG) affects approximately 50,000 patients or about 1% of the overall population of patients with gout in the United States of America. The severity of TFG is manifested by frequent acute attacks of disabling arthritis, chronic deforming joint disease, destructive masses of urate crystals (tophi), progressive physical disability, and poor health-related quality of life. Pegloticase (Krystexxa(®); Savient Pharmaceuticals, Inc), a novel PEGylated urate oxidase (uricase) enzyme, has been resubmitted for US Food and Drug Administration approval. In a 6-month, placebo-controlled clinical trial, 8 mg of pegloticase for every 2 weeks induced a lytic decrease of serum urate (sUr) concentrations, leading to dissolution of tophi in 40% of patients at final visit. However, 58% were nonresponders to the defined target sUr of 0.36 mmol/L (80% were nonresponders during months 3 and 6), possibly due to anti-body formation. Also, 26%-31% experienced infusion reactions (IRs) and 77% suffered from gout flares. Although long-term data are awaited, an anti-inflammatory strategy, eg, based on glucocorticosteroids, is needed to prevent pegloticase antibody formation leading to IRs and diminished or shortened efficacy, and might also prevent gout flares. According to the current clinical data, pegloticase might have an important role as a (bridging) treatment in sUr-responsive patients for tophi clearance in severe chronic refractory gout.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.